Pharvaris CMO Lu Peng discloses option and share holdings

(Moderate)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Pharvaris N.V. Chief Medical Officer Lu Peng reported her initial ownership in a Form 3 filing. She directly holds 66,309 shares of common stock as of March 18, 2026, which includes restricted stock units that settle in common shares.

She also holds multiple stock option awards on common stock with various exercise prices and long-dated expirations. These include options covering 245,308 shares at an exercise price of $2.59 per share expiring in 2030, and additional grants at higher exercise prices expiring between 2031 and 2036. Many of these options and RSUs vest 25% on a specified date, with the remaining portion vesting in equal monthly installments over four years.

Insider Trade Summary

11 transactions reported

Mixed 11 txns

Insider Lu Peng

Role Chief Medical Officer

Type	Security	Shares	Price	Value
holding	Stock Option (Right to Buy)	--	--	--
holding	Stock Option (Right to Buy)	--	--	--
holding	Stock Option (Right to Buy)	--	--	--
holding	Stock Option (Right to Buy)	--	--	--
holding	Stock Option (Right to Buy)	--	--	--
holding	Stock Option (Right to Buy)	--	--	--
holding	Stock Option (Right to Buy)	--	--	--
holding	Stock Option (Right to Buy)	--	--	--
holding	Stock Option (Right to Buy)	--	--	--
holding	Stock Option (Right to Buy)	--	--	--
holding	Common Stock	--	--	--

Holdings After Transaction: Stock Option (Right to Buy) — 671,778 contracts (Direct); Common Stock — 66,309 shares (Direct)

Footnotes (10)

F1. Includes restricted stock units previously granted under the Company's equity plan that remain outstanding as of March 18, 2026. The awards settle in shares of common stock and are reported in Table I as non-derivative securities. Vesting occurs as follows: - 25,000 RSUs from an award granted March 3, 2026 of which 25% will vest March 3, 2027 with the remainder vesting monthly thereafter; -17,250 RSUs from an award granted March 12, 2025 of which 25% vested March 12, 2026 with the remainder vesting monthly thereafter; -11,120 RSUs from an award granted April 11, 2024 of which 25% vested April 11, 2025 with the remainder vesting monthly thereafter.
F2. 25% of the option will vest on March 3, 2027 with the remaining shares vesting in 1/48 monthly installments thereafter.
F3. 25% of the option vested on March 12, 2026 with the remaining shares vesting in 1/48 monthly installments thereafter.
F4. 25% of the option vested on April 11, 2025 with the remaining shares vesting in 1/48 monthly installments thereafter.
F5. 25% of the option vested on April 6, 2024 with the remaining shares vesting in 1/48 monthly installments thereafter.
F6. 25% of the option vested on January 6, 2026 with the remaining shares vesting in 1/48 monthly installments thereafter.
F7. 25% of the option vested on April 1, 2023 with the remaining shares vesting in 1/48 monthly installments thereafter.
F8. 25% of the option vested on January 1, 2025 with the remaining shares vesting in 1/48 monthly installments thereafter.
F9. 25% of the option vested on February 5, 2022 with the remaining shares vesting in 1/48 monthly installments thereafter.
F10. 25% of the option vested on February 3, 2021 with the remaining shares vesting in 1/48 monthly installments thereafter.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Pharvaris (PHVS) Chief Medical Officer Lu Peng report in this Form 3?

Lu Peng reports her initial ownership as Chief Medical Officer, including 66,309 Pharvaris common shares and several stock option grants. The filing outlines her equity-based compensation structure, vesting schedules, and long-dated option expirations across multiple grant years.

How many Pharvaris (PHVS) common shares does Lu Peng hold according to the Form 3?

Lu Peng directly holds 66,309 shares of Pharvaris common stock as of March 18, 2026. This figure includes restricted stock units that settle in common shares, reflecting both vested and unvested equity awards reported as non-derivative securities in the filing.

What stock option awards are disclosed for Lu Peng in the Pharvaris (PHVS) Form 3?

The Form 3 lists multiple stock option grants giving Lu Peng rights to buy Pharvaris common shares at preset exercise prices. One key grant covers 245,308 shares at $2.59 per share expiring in 2030, with additional options expiring from 2031 through 2036 at higher exercise prices.

How do Lu Peng’s Pharvaris (PHVS) RSU awards vest over time?

Her RSU awards generally vest 25% on a specified first vesting date, with the remaining 75% vesting in equal monthly installments over four years. The filing details RSUs granted in 2024, 2025, and 2026, each following this 25% cliff and monthly vesting structure.

What are the typical vesting terms for Lu Peng’s Pharvaris (PHVS) stock options?

Most stock option grants to Lu Peng vest 25% on an initial vesting date, with the balance vesting in 1/48 monthly installments thereafter. The footnotes specify this pattern for options granted across several years, covering expirations from 2030 to 2036.

Does the Pharvaris (PHVS) Form 3 show any recent buy or sell transactions by Lu Peng?

The Form 3 functions as an initial ownership report and does not show explicit buy or sell transactions. It primarily lists Lu Peng’s existing holdings in Pharvaris common stock, restricted stock units, and stock options with their associated vesting and expiration terms.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 03/18/2026 - 02:23 PM EDT

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Lu Peng

(Last)

(First)

(Middle)

1 CRANBERRY HILL SUITE 400

(Street)

LEXINGTON

MASSACHUSETTS

02421

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
Pharvaris N.V. [ PHVS ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Medical Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	66,309⁽¹⁾	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Stock Option (Right to Buy)	⁽²⁾	03/03/2036	Common Stock	70,000	$28	D
Stock Option (Right to Buy)	⁽³⁾	03/12/2035	Common Stock	67,500	$16.05	D
Stock Option (Right to Buy)	⁽⁴⁾	04/11/2034	Common Stock	65,000	$22.31	D
Stock Option (Right to Buy)	⁽⁵⁾	04/06/2033	Common Stock	73,118	$8.05	D
Stock Option (Right to Buy)	⁽⁶⁾	04/06/2033	Common Stock	6,882	$8.05	D
Stock Option (Right to Buy)	⁽⁷⁾	04/01/2032	Common Stock	57,669	$18.14	D
Stock Option (Right to Buy)	⁽⁸⁾	04/01/2032	Common Stock	7,301	$18.14	D
Stock Option (Right to Buy)	⁽⁹⁾	02/05/2031	Common Stock	14,000	$20	D
Stock Option (Right to Buy)	⁽⁹⁾	02/05/2031	Common Stock	65,000	$20	D
Stock Option (Right to Buy)	⁽¹⁰⁾	02/03/2030	Common Stock	245,308	$2.59	D

Explanation of Responses:

1. Includes restricted stock units previously granted under the Company's equity plan that remain outstanding as of March 18, 2026. The awards settle in shares of common stock and are reported in Table I as non-derivative securities. Vesting occurs as follows: - 25,000 RSUs from an award granted March 3, 2026 of which 25% will vest March 3, 2027 with the remainder vesting monthly thereafter; -17,250 RSUs from an award granted March 12, 2025 of which 25% vested March 12, 2026 with the remainder vesting monthly thereafter; -11,120 RSUs from an award granted April 11, 2024 of which 25% vested April 11, 2025 with the remainder vesting monthly thereafter.

2. 25% of the option will vest on March 3, 2027 with the remaining shares vesting in 1/48 monthly installments thereafter.

3. 25% of the option vested on March 12, 2026 with the remaining shares vesting in 1/48 monthly installments thereafter.

4. 25% of the option vested on April 11, 2025 with the remaining shares vesting in 1/48 monthly installments thereafter.

5. 25% of the option vested on April 6, 2024 with the remaining shares vesting in 1/48 monthly installments thereafter.

6. 25% of the option vested on January 6, 2026 with the remaining shares vesting in 1/48 monthly installments thereafter.

7. 25% of the option vested on April 1, 2023 with the remaining shares vesting in 1/48 monthly installments thereafter.

8. 25% of the option vested on January 1, 2025 with the remaining shares vesting in 1/48 monthly installments thereafter.

9. 25% of the option vested on February 5, 2022 with the remaining shares vesting in 1/48 monthly installments thereafter.

10. 25% of the option vested on February 3, 2021 with the remaining shares vesting in 1/48 monthly installments thereafter.

	/s/ Marnus Nel, Attorney-in-Fact for Peng Lu	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

Source: View Original Filing on SEC EDGAR